Carl Dambkowski Sells 22,417 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Director Carl Dambkowski sold 22,417 shares of Oruka Therapeutics stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $70.13, for a total transaction of $1,572,104.21. Following the completion of the sale, the director owned 51,326 shares in the company, valued at approximately $3,599,492.38. This trade represents a 30.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Friday, June 12th, Carl Dambkowski sold 12,583 shares of Oruka Therapeutics stock. The stock was sold at an average price of $70.11, for a total value of $882,194.13.
• On Thursday, May 21st, Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $58.97, for a total transaction of $6,191,850.00.

Oruka Therapeutics Trading Up 2.1%

NASDAQ ORKA traded up $1.42 on Friday, reaching $69.89. 781,454 shares of the company were exchanged, compared to its average volume of 1,072,342. The stock has a market capitalization of $4.22 billion, a P/E ratio of -36.03 and a beta of -0.26. The business’s fifty day moving average price is $63.01 and its 200 day moving average price is $43.76. Oruka Therapeutics, Inc. has a fifty-two week low of $10.77 and a fifty-two week high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. Equities research analysts forecast that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.

Institutional Trading of Oruka Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada grew its position in shares of Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares during the period. Los Angeles Capital Management LLC purchased a new stake in shares of Oruka Therapeutics in the fourth quarter worth about $37,000. PNC Financial Services Group Inc. acquired a new position in shares of Oruka Therapeutics during the third quarter worth $39,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Oruka Therapeutics in the fourth quarter worth about $67,000. Finally, Russell Investments Group Ltd. acquired a new stake in Oruka Therapeutics in the third quarter valued at $43,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ORKA has been the subject of several recent research reports. Wedbush set a $165.00 price objective on shares of Oruka Therapeutics in a research note on Monday, April 27th. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 16th. Barclays increased their price target on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research note on Monday, April 27th. UBS Group upped their price target on Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Finally, Stifel Nicolaus increased their price target on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday, March 13th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $131.30.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.